Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 61 clinical trials
Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA

The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence. The aim of the current study is to improve the rate and the quality of hematologic response as well as …

  • 39 views
  • 21 Mar, 2021
  • 1 location
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)

This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/L on two counts no sooner than 7 days apart in the 15 days before …

platelet count
thrombocytopenia
autoimmune thrombocytopenia
  • 450 views
  • 23 Jul, 2021
  • 64 locations
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/L on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg twice daily.

platelet count
thrombocytopenia
  • 0 views
  • 24 Jul, 2021
  • 51 locations
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for 6 Months

A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for 6 Months

avatrombopag
thrombocytopenia
  • 13 views
  • 14 Aug, 2021
  • 37 locations
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

Primary Objective: To evaluate the effect of BIVV020 on the durability of platelet response in participants with persistent/chronic immune thrombocytopenia (ITP) Secondary Objectives: To assess the safety and tolerability of BIVV020 To assess the pharmacokinetics of BIVV020 To assess the response rate of treatment with BIVV020 To assess the time …

platelet count
thrombopoietin receptor agonists
immune globulin
rituximab
cyclophosphamide
  • 1 views
  • 18 Aug, 2021
  • 9 locations
A First in HumanTrial to Evaluate The Safety Tolerability And Pharmacokinetics Of PF-06755347

This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult male subjects. The pharmacokinetics and pharmacodynamics will also be evaluated.

heart failure
administered intravenously
malignancy
cancer
  • 167 views
  • 30 Aug, 2021
  • 6 locations
  • 20 views
  • 14 May, 2021
  • 16 locations
The DART Study- Daratumumab Treatment in ITP

A multicenter clinical, open-label total dose-escalating phase II study with safety run-in to explore the clinical activity, total dosage, and safety of daratumumab in adult ITP patients who have not responded adequately or relapsed after corticosteroids and at least one second-line therapy including rituximab and/or TPO-RA.

steroid therapy
rituximab
platelet count
corticosteroids
  • 0 views
  • 06 Sep, 2021
  • 6 locations
The PROLONG Trial - Rituximab Maintenance Therapy in ITP

This study is a two phase study that aims to evaluate if low-dose Rituximab maintenance therapy may prolong the the effect of Rituximab in immune thrombocytopenia.

platelet count
rituximab
dexamethasone
prednisone
thrombocytopenia
  • 142 views
  • 26 Jan, 2021
  • 1 location
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this

platelet count
KIT
kidney function tests
rituximab
romiplostim
  • 0 views
  • 14 Aug, 2021
  • 1 location